Articles
Medical evidence, explained so you can decide about your health.
Medical guides by treatment
All guides, newest first
Finasteride for hair loss: how it works, results and side effects
Finasteride is one of the treatments authorised in Spain for androgenetic alopecia in men. We explain how it acts on DHT, what the trials show, which side effects the EMA has been monitoring since 2025 and why the decision is always an individual medical assessment.
Jul 24, 2026
Fezolinetant (Veoza): the new non-hormonal pill for hot flushes
Veoza is the first non-hormonal medicine authorised in Spain for moderate to severe menopausal hot flushes. What it is, what the SKYLIGHT trials found and why it requires liver monitoring.
Jul 22, 2026
Perimenopause: what it is, when it starts and how long it lasts
Perimenopause is the transition towards menopause, not a single point in time. We explain what it is, why it happens, how long it usually lasts and what the evidence says about the symptoms and their treatments, with nuance and without scaremongering.
Jul 22, 2026
Androgenetic alopecia: why hair falls out and how far it goes
Androgenetic alopecia is the most common cause of hair loss and comes down to a mix of hormones and genetics. Here's what happens inside the follicle, how it progresses and which myths are worth leaving behind.
Jul 20, 2026
Enclomiphene and clomiphene: raising testosterone without shutting down fertility
Two drugs that raise your own testosterone without switching off fertility. The idea looks good on paper; the problem is that neither the EMA nor the FDA approved them for that, and in Spain they are not authorised for use in men.
Jul 20, 2026
Metabolic fatty liver disease: what it is, why it happens and what can be done
Metabolic fatty liver disease (MASLD) affects more than 30% of adults and is closely tied to weight, insulin resistance and diabetes. Here we explain what it is, why it happens, what the evidence says about losing weight and the new medicines, and which myths are worth dismantling.
Jul 20, 2026
Orforglipron (Foundayo): the first GLP-1 pill with no restrictions, and why it isn't available in Spain
The FDA approved orforglipron in April 2026 under the brand name Foundayo. It is a daily tablet that can be taken at any time of day, with no fasting and no water restriction. It is not authorised in Spain. Here is what its trials actually show.
Jul 17, 2026
Retatrutide: what its phase 3 trial found, and why you can't get hold of it
Lilly announced the TRIUMPH-1 results: −28.3% body weight at 80 weeks. Here's what that figure says, what it doesn't say, and why retatrutide isn't authorised in any country in the world.
Jul 17, 2026
CagriSema: what it is, what the REDEFINE trials found and why it disappointed
Novo Nordisk combined semaglutide with cagrilintide expecting 25% weight loss. It came out at 22.7%, and when it was measured head to head against tirzepatide, it lost. What the data say and where it stands today.
Jul 17, 2026
Buying Ozempic and Mounjaro in Spain: how to get them legally and safely
How to obtain Ozempic and Mounjaro legally in Spain. The legitimate routes, the risks of buying without a prescription, real prices and what to look for in a serious medical service.
Jun 28, 2026
Ozempic and Mounjaro side effects: what to expect and how to manage them
Ozempic and Mounjaro side effects: what to expect, how they are managed clinically and why proper medical follow-up makes all the difference.
Jun 28, 2026
GLP-1: what it is, how it works and why it is transforming obesity treatment
What the GLP-1 hormone is, how pharmacological GLP-1 agonists work, which medicines are available in Spain (Ozempic, Wegovy, Mounjaro) and what the clinical evidence shows.
Jun 28, 2026
It's time to reach your goal.
Online medical assessment, prescription when appropriate and 1:1 follow-up with this team.
Start assessment